Compare Novo Nordisk A/S (NVO) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Trade Desk Inc — how do they compare? Novo Nordisk A/S trades at $49.31 (market cap $220.53B), while Trade Desk Inc trades at $18.26 (market cap $8.76B). The key difference: Novo Nordisk A/S is far larger — about 25.2× Trade Desk Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| NVO | TTD | |
|---|---|---|
Market Cap | $220.53B | $8.76B |
Sector | Health | Technology |
52-Week High | $71.70 | $89.76 |
52-Week Low | $35.29 | $17.33 |
Enterprise Value | $239.49B | $7.78B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
The Trade Desk (TTD) trades at $18.25, down 1.83% with bearish technical signals. Revenue grew to $2.9B in 2025 with strong 77.8% gross margins, though Q1 2026 EPS missed expectations. Recent executive appointments and the Publicis dispute settlement provide operational stability. The stock faces headwinds from slowing growth and competitive pressure from tech giants.
TTD presents a value opportunity at 21x P/E with 49% analyst buy ratings and $25.23 price target upside. Risks include persistent revenue deceleration and market share loss to walled gardens. The company's profitability and strategic partnerships support long-term potential despite near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
